Research

CUHK-led International Study Demonstrates Immunotherapy Is Effective in Patients with Advanced Nasopharyngeal Cancer

10 May 2018

Mr CHAN (pseudo name, right), an NPC patient, states that his physical condition and life quality were not seriously affected during immunotherapy, and there were fewer side effects than chemotherapy

Mr CHAN (pseudonym, right), an NPC patient, states that his physical condition and life quality were not seriously affected during immunotherapy, and that he suffered fewer side effects than with chemotherapy.

Abstract

Our researchers led an international study that demonstrated the anti-tumour activity of the immune-checkpoint inhibitor in recurrent and metastatic nasopharyngeal cancer (NPC) patients. Results showed the 1-year overall survival rate to be around 60%. Further analysis facilitated the identification of biomarkers and the development of immunotherapy in NPC patients. The findings of this landmark study have been published in the Journal of Clinical Oncology.

Details: http://bit.ly/2G1E7eP

Back to Listing page

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Research Uncovers the Mechanisms of Liver Cancer Induced by Non-Alcoholic Fatty Liver Disease in Mice